Momentum Continues as Depth of Clinical Experience Expands Worldwide MARLTON, N.J., May 15, 2023 (GLOBE NEWSWIRE) — Impulse Dynamics plc, a global medical device company dedicated to improving the lives of people with heart failure (HF), announced today a worldwide milestone achievement with the 9,000th patient receiving the Optimizer® system for […]
Other News
InspireMD Announces Private Placement of Up to $113.6 Million
Led by Marshall Wace with participation from OrbiMed, Rosalind, Nantahala, Soleus, Velan and certain InspireMD Board members $42.2 million financing upfront with up to an additional $71.4 million tied to exercise of milestone-driven warrants TEL AVIV, Israel and MIAMI, May 15, 2023 (GLOBE NEWSWIRE) — InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention […]
Verve Therapeutics Announces Pipeline Progress and Expansion and Reports First Quarter 2023 Financial Results
heart-1 Clinical Trial of VERVE-101 Ongoing with Initial Data Expected in the Second Half of 2023 VERVE-102 Named Second PCSK9-Targeting Program, Leveraging Novel GalNAc-LNP Delivery with Clinical Trial Initiation Expected in the First Half of 2024 VERVE-201 Targeting ANGPTL3 Progressing with Clinical Trial Initiation Expected in the Second Half of […]
Hyperfine, Inc. Reports First Quarter 2023 Financial Results
GUILFORD, Conn., May 11, 2023 (GLOBE NEWSWIRE) — Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking medical device company that created the Swoop® system, the world’s first FDA-cleared portable, point-of-care MRI system, today announced first quarter 2023 financial results and provided a business update. “We had strong growth at Hyperfine in the […]
Supira Medical’s Percutaneous Ventricular Assist Device (pVAD) to be Highlighted During PCR Innovator’s Day and SCAI 2023
Supira’s technology features a novel low profile, high continuous flow design that aims to provide full hemodynamic support for high-risk percutaneous coronary interventions (HRPCI) and cardiogenic shock (CS) patients with a single device Data from the Company’s First-in-Human trial to be presented as part of the Late-Breaking Clinical Research Session […]
Amarin Highlights New Data Providing Potential Mechanistic Insight into Vascepa®/Vazkepa® (Icosapent Ethyl) Reduction of Cardiovascular Events
— New Research Demonstrates Multifactorial Beneficial Effects of VASCEPA/VAZKEPA on Coronary Physiology and Plaque Progression — –Data Further Advances Understanding of VASCEPA/VAZKEPA Potential Mechanism of Action– DUBLIN, Ireland and BRIDGEWATER, N.J., May 12, 2023 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN) today highlighted new data describing the benefits of VASCEPA®/VAZKEPA® (icosapent […]
Stanford Medicine Named Winner of the 2023 Hearst Health Prize in Partnership with the UCLA Center for SMART Health
$100,000 prize awarded for Stanford Medicine’s AI solution for identifying people with heart attack risk LOS ANGELES, May 12, 2023 /PRNewswire/ — The UCLA Center for SMART Health, an interdisciplinary collaborative that looks to the integrated transformation of healthcare through emergent data and technologies, and Hearst Health, a division of Hearst and leader […]
Acutus Medical Reports First Quarter 2023 Financial Results
CARLSBAD, Calif., May 11, 2023 (GLOBE NEWSWIRE) — Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today reported results for the first quarter of 2023. Recent Highlights: Reported revenue of $4.2 million for the […]
Humacyte First Quarter 2023 Financial Results and Business Update
– Human Acellular Vessel™ (HAV™) granted second RMAT designation by the FDA, for Vascular Trauma – – Completion of enrollment in Phase 3 trial of HAV in Hemodialysis Access in End-Stage Renal Disease Patients – – Conference call and live webcast at 8:00 a.m. ET today – DURHAM, N.C., May […]
Longeveron Inc. Provides Corporate Update and Reports First Quarter 2023 Financial Results
— New long-term survival data disclosed from ELPIS I trial of Lomecel-BTM for Hypoplastic Left Heart Syndrome; Data reinforce potential mortality benefit — — First patient dosed in Phase 2 clinical trial of Lomecel-BTM for Aging-Related Frailty in Japan — — Conference call scheduled for 8:30 a.m. ET today — MIAMI, May […]



